Share Buyback

A new report reveals investors are hungry for growth, pushing firms to reinvest, but high valuations and global uncertainty temper their bullish outlook.

The successful offering highlights investor appetite for structured income products tied to Canada's resilient banking sector amid economic uncertainty.

Amid a bold pivot to blockchain, Sharps Technology doubles down with an advisor lock-up and a $100M buyback, signaling conviction in its hybrid future.

A new Egan-Jones report argues that while founders get the fame, it's the successor CEOs at Apple, Microsoft, and Alphabet who build enduring value.

With global milk oversupply and shifting consumer tastes, all eyes are on Saputo's Feb. 5 earnings for signs of strategic success and market health.

As foreign investors accumulate shares at valuation lows, Shoucheng Holdings leverages its financial might and strategic robotics portfolio to redefine its future.

As MarketAxess preps its Q4 results, investors weigh a mixed 2025. Will its strategic shifts in a volatile fixed-income market deliver on growth promises?

Antero Midstream announces its 45th straight dividend and a $48M share buyback, signaling financial strength as investors await Q4 2025 earnings.

With a promising brain injury drug and no approved rivals, Oragenics heads to a tax-haven investor summit to secure funding for its next critical phase.

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

Investors and HR leaders watch as Unum prepares to release its Q4 results and 2026 strategy in a rapidly evolving workplace benefits landscape.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

EfTEN Real Estate Fund reports its best-ever operating results, proposing an 8% dividend hike, while a minor portfolio revaluation hints at market shifts.

Hong Kong's 3E Network completes a $2M financing round, fueling its strategic shift into the competitive global AI infrastructure market.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

Operational failures at a key Texas plant and a sudden drop in chlorine demand force chemical giant Olin Corp. to drastically cut its Q4 earnings forecast.

Kim Neville’s return from an in-house VP role signals a strategic play in Utah’s hot legal market and highlights a growing industry talent trend.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

As legacy brand Hamilton Beach heads to a major conference, its high-stakes pivot from kitchen gadgets to health tech will be under the microscope.